A multicenter prospective study on the usefulness of metallic stents of long covers for biliary obstruction caused by unresectable middle-lower bile duct malignant tumors

A multicenter prospective study on the usefulness of metallic stents of long covers for biliary obstruction caused by unresectable middle-lower bile duct malignant tumors - A multicenter prospective study on the usefulness of metallic stents of long covers for biliary obstruction caused by unresectable middle-lower bile duct malignant tumors

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016252

Enrollment

Registered

2015-01-23

Start date

2015-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Middle-lower bile duct obstruction caused by malignant tumors such as pancreas cancer,papilla Vater cancer,bile duct cancer,gallbladder cancer,malignant lymphoma,lymph node metastasis,etc

Interventions

We will place metallic stents of long covers for biliary obstruction caused by unresectable middle-lower bile duct malignant tumors into the obstructive portion and research duration until stent dysfu

Up to the day passed 12 months from the day started to follow the last registrant(30th case).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Cases of biliary obstruction caused by middle-lower bile duct malignant tumors 2.As a general rule, cases in which a pathological definitive diagnosis was obtained (regardless of whether they were cases of cytodiagnosis or histological diagnosis). In addition, even if, for some reason or other, a pathological definitive diagnosis was not obtained, cases in which a clear diagnosis was obtained through such means as clinical findings, tumor markers, US, CT, MRI, etc. were also used as subjects for investigation. 3.Cases for which no plans have been made for carrying out radical resection. 4.Concerning participation in the study, patients who provide informed consent (as a general rule, the patients must be carried out of cancer notification).

Exclusion criteria

Exclusion criteria: 1.Cases in which informed consent cannot be obtained 2. Cases in which there was poor first biliary tract drainage 3.Others, including cases in which the principal investigator (or sub-investigator) in the study judges the patient to be unsuitable as a subject for the investigation such as cases of severe dysfunction of the cardiopulmonary performance, dementia, etc.

Design outcomes

Primary

Measure	Time frame
Duration until stent dysfunction	—

Secondary

Measure	Time frame
Overall survival, Kinds and frequency of the complication, A effective rate of the stent in the time of death	—

Countries

Japan

Contacts

Public ContactMitsuo Tokuhara

Daito-central hospital internal medicine department

tokuman.am@wing.ocn.ne.jp072-870-0200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026